Thank you to the shareholder who brought this post to my...

Thank you to the shareholder who brought this post to my attention. To clarify post #7007825 from GeminiJoel:

Gemini: "The standard criteria for measuring statistical significance is ACR20 - a 20% improvement in signs and symptoms."

Not exactly. As detailed in the release, the ACR criteria is the American College of Rheumatology (ACR) standardized measure of improvement in rheumatoid arthritis symptoms and is a complex composite measure that considers tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant such as sedimentation rate, patient assessment, physician assessment, pain scale and disability/functional questionnaire. ACR20 records the percentage of patients with at least a 20% improvement in signs and symptoms of rheumatoid arthritis.

Statistical significance is just that - a result that is significant statistically, for example a statistic with a probability value of p < 0.001.

**
Gemini: "The placebo was methotrexate (MTX). This is the "gold standard" of current treatments. It was not a sugar pill."

Not exactly. The placebo was placebo. However, as detailed in the release the study was in patients with moderate to severe rheumatoid arthritis despite treatment with methotrexate. All patients in this study continued on their maximum tolerated dose of methotrexate throughout the study. Methotrexate is the standard therapy used to treate RA. See American College of Rheumatology for more. http://www.rheumatology.org/practice/clinical/patients/medications/methotrexate.asp

**
Gemini: "Sub optimal dosing. 75mg of XToll delivered subcutaneously (into the skin) was not the equivalent of doses previously delivered intravenously".

As detailed in the release, a review indicates that the highest dose, 75mg, used in this trial was a sub-optimal dose and not equivalent to that achieved in the earlier IV studies. This finding supports the need to use higher doses in a dose-ranging study in order to determine the optimal doses of drug.

**
Gemini: "Management believe continued investigation of XToll is warranted at higher doses"

As detailed in the release: ?I believe these results indicate that we are seeing a real clinical effect. The signals at this time continue to point to a good safety profile. It is the view of the Board these results warrant the continued investigation of XToll? said Mr Stephen Jones, CBio Executive Chairman. ?Commercialisation discussions with global pharmaceutical companies continue. The next step is a clinical trial to determine the optimal dose of XToll? with subcutaneous administration,? said CBio?s Managing Director Mr Jason Yeates.


**
I hope this is of assistance.